Scly - selenocysteine lyase Gene
Also Known as SCL; Scly1; Scly2; 9830169H08; A930015N15Rik
Species: Mus musculus
Gene Type: protein coding
Gene ID: 50880
Summary
Predicted to enable several functions, including protein homodimerization activity; selenocysteine lyase activity; and vitamin B6 binding activity. Acts upstream of or within several processes, including negative regulation of cellular response to oxidative stress; response to insulin; and selenium compound metabolic process. Predicted to be located in Golgi apparatus. Predicted to be part of catalytic complex. Is expressed in alimentary system; liver; and nervous system. Orthologous to human SCLY (selenocysteine lyase). [provided by Alliance of Genome Resources, Apr 2022]
Scly Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_016717.3 | NP_057926.2 | selenocysteine lyase |
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| acts upstream of or within lipid metabolic process |
IMP
IMP: Inferred from mutant phenotype
|
22890841 | MGI |
| acts upstream of or within negative regulation of cellular response to oxidative stress |
IMP
IMP: Inferred from mutant phenotype
|
22890841 | MGI |
| acts upstream of or within response to insulin |
IMP
IMP: Inferred from mutant phenotype
|
22890841 | MGI |
| acts upstream of or within selenium compound metabolic process |
IMP
IMP: Inferred from mutant phenotype
|
22890841 | MGI |
EXP: Inferred from Experiment
IDA: Inferred from direct assay
IPI: Inferred from physical interaction
IMP: Inferred from mutant phenotype
IGI: Inferred from genetic interaction
IEP: Inferred from expression pattern
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
selenocysteine lyase |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(15)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-B0361 | Aspartame | 99.70% | Unkown | |
| HY-17474 | Parecoxib | Inhibitor | 99.29% | Yes |
| HY-132587 | Fitusiran | 98.70% | Unkown | |
| HY-17474A | Parecoxib Sodium | Inhibitor | 99.82% | Yes |
| HY-B0561R | Spironolactone (Standard) | 98.55% | Unkown | |
| HY-17509 | Deracoxib | 99.96% | Unkown | |
| HY-132587A | Fitusiran sodium | 95.08% | Unkown | |
| HY-B0455A | Lomefloxacin | 99.99% | Unkown | |
| HY-B0318A | Metronidazole hydrochloride | 98.44% | Yes | |
| HY-B1341 | Norethynodrel | Activator | 90.53% | Unkown |
| HY-132587C | Fitusiran sodium scrambled negative control | Activator | / | Unkown |
| HY-132587D | FAM labled Fitusiran sodium | / | Unkown | |
| HY-132587E | Cy3 labled Fitusiran sodium | / | Unkown | |
| HY-B0455AR | Lomefloxacin (Standard) | Inhibitor | / | Unkown |
| HY-B0455B | Lomefloxacin (aspartate) | Inhibitor | / | Unkown |
Inhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P99590 | Sotatercept | 99.94% | Unkown |
Clinical Phase
Bioactive Molecules
(16)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-14718 | Resminostat | Inhibitor | 99.44% | Phase 4 |
| HY-14398GL | Celecoxib (GMP Like) | Inhibitor | / | Phase 4 |
| HY-170554 | ABBV-706 | Inhibitor | 99.71% | Phase 3 |
| HY-132257 | Rovalpituzumab tesirine | Inhibitor | 97.47% | Phase 3 |
| HY-U00232 | Bidisomide | Ligand | 99.62% | Phase 3 |
| HY-136657 | SC-43 | 99.01% | Phase 2 | |
| HY-16012 | Domatinostat tosylate | 99.66% | Phase 2 | |
| HY-106395 | Telinavir | Inhibitor | 98.16% | Phase 2 |
| HY-100934 | SC-9 | Activator | 99.33% | Phase 2 |
| HY-14908A | Vidofludimus hemicalcium | / | Phase 2 | |
| HY-19046 | AGN-2979 hydrochloride | Inhibitor | / | Phase 2 |
| HY-19080 | SC-45662 | Inhibitor | / | Phase 2 |
| HY-19500 | SC-75416 | Inhibitor | / | Phase 2 |
| HY-16451 | SC-49483 | / | Phase 2 | |
| HY-19897 | 4SC-203 | Inhibitor | 98.98% | Phase 1 |
| HY-112739 | SC-41930 | Agonist | / | Phase 1 |
Inhibitory Antibodies
(1)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase
|
|---|---|---|---|---|
| HY-P99886 | Pexelizumab | Inhibitor | 99.0% | Phase 3 |
Pre-clinical Phase
Bioactive Molecules
(171)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-18749 | SC79 | Activator | 98.0% | Unkown |
| HY-107410 | SC-26196 | Inhibitor | 99.66% | Unkown |
| HY-10496 | SC75741 | Inhibitor | 99.24% | Unkown |
| HY-148559 | 4A3-SC8 | 99.93% | Unkown | |
| HY-15614 | SC144 | 99.48% | Unkown | |
| HY-145799 | 5A2-SC8 | Chemical | 99.89% | Unkown |
| HY-59105 | SC-560 | Inhibitor | 99.87% | Unkown |
| HY-13802 | SC-514 | Inhibitor | 99.97% | Unkown |
| HY-145758 | FEN1-IN-SC13 | Inhibitor | 98.42% | Unkown |
| HY-126681 | SC-VC-PAB-MMAE | 99.07% | Unkown | |
| HY-140698 | m-PEG5000-NHS ester | 95.0% | Unkown | |
| HY-W591424 | m-PEG2000-NHS ester | Ligand | 95.89% | Unkown |
| HY-15614A | SC144 hydrochloride | 98.98% | Unkown | |
| HY-161409 | SC912 | 99.13% | Unkown | |
| HY-124876 | SynuClean-D | Inhibitor | 99.89% | Unkown |
| HY-103226 | SC-57461A | Inhibitor | 99.93% | Unkown |
| HY-16012A | Domatinostat | 99.34% | Unkown | |
| HY-P0323A | GP(33-41) TFA | Inhibitor | 99.62% | Unkown |
| HY-18086 | TCS PIM-1 1 | Inhibitor | 98.40% | Unkown |
| HY-108562 | SC-51322 | Antagonist | 98.93% | Unkown |
| HY-Y0079S | D-Phenylalanine-d5 | 99.92% | Unkown | |
| HY-W010983 | SC-236 | 99.59% | Unkown | |
| HY-19832 | SC66 | 99.65% | Unkown | |
| HY-157745 | m-PEG40000-NHS ester | 98.0% | Unkown | |
| HY-144880 | SC209 | Inhibitor | 98.99% | Unkown |
| HY-101955A | (2R,6R)-Hydroxynorketamine hydrochloride | 99.91% | Unkown | |
| HY-164373 | SC428 | 98.0% | Unkown | |
| HY-158031 | PLK1/BRD4-IN-5 | 98.80% | Unkown | |
| HY-100931 | SC-10 | Activator | 99.59% | Unkown |
| HY-108563A | SC 51089 free base | Antagonist | 98.60% | Unkown |
| HY-131236 | EBNA1-IN-SC7 | 98.37% | Unkown | |
| HY-145799A | 5A2-SC8 TFA | Chemical | 98.85% | Unkown |
| HY-155656 | Anti-inflammatory agent 49 | Inhibitor | 99.44% | Unkown |
| HY-203862 | Polyquaternium-51 | / | Unkown | |
| HY-P10827 | PIC1 PA | Inhibitor | 98.37% | Unkown |
| HY-140699 | m-PEG10000-NHS ester | 98.0% | Unkown | |
| HY-W013164 | SC-58125 | Inhibitor | 99.92% | Unkown |
| HY-Y0079S1 | D-Phenylalanine-d8 | 98.28% | Unkown | |
| HY-114857 | Clofencet | 98.62% | Unkown | |
| HY-120113 | SC-2001 | 99.37% | Unkown | |
| HY-124858 | SC99 | 98.90% | Unkown | |
| HY-177069 | 4A3-SC7 | 98.55% | Unkown | |
| HY-118827 | Vedaprofen | Inhibitor | 98.73% | Unkown |
| HY-138865 | BiCAPPA | Inhibitor | 98.35% | Unkown |
| HY-140700 | m-PEG20000-NHS ester | 98.0% | Unkown | |
| HY-N9319 | Fulvotomentoside A | 99.76% | Unkown | |
| HY-102065 | SC-19220 | 99.86% | Unkown | |
| HY-171099 | SC-919 | Inhibitor | 98.68% | Unkown |
| HY-132306 | CCF0058981 | Inhibitor | 98.02% | Unkown |
| HY-148194 | SC239 | 99.97% | Unkown | |
| HY-124775 | (S)-C33 | Inhibitor | 99.46% | Unkown |
| HY-126693 | SC-VC-PAB-DM1 | 97.04% | Unkown | |
| HY-129982 | SC-435 | 99.14% | Unkown | |
| HY-B0561S | Spironolactone-d7 | 99.96% | Unkown | |
| HY-47968 | SC209 intermediate-1 | ≥96.0% | Unkown | |
| HY-106395A | (Rac)-Telinavir | Inhibitor | / | Unkown |
| HY-108563 | SC 51089 | Antagonist | 98.64% | Unkown |
| HY-148402 | p53 Activator 3 | Activator | 98.35% | Unkown |
| HY-148404 | p53 Activator 5 | Activator | 98.43% | Unkown |
| HY-148528 | SC-VC-PAB-N-Me-L-Ala-Maytansinol | 98.66% | Unkown | |
| HY-B0455S | Lomefloxacin-d5 hydrochloride | 99.88% | Unkown | |
| HY-B0561S1 | Spironolactone-d3 | 99.87% | Unkown | |
| HY-P3326A | Targeting the bacterial sliding clamp peptide 46 TFA | Inhibitor | 99.83% | Unkown |
| HY-W009934 | 2-Phenyl-2-(2-pyridyl)acetonitrile | 99.97% | Unkown | |
| HY-W028047 | JFD01307SC | Inhibitor | 98.0% | Unkown |
| HY-U00129 | SC57666 | Inhibitor | 98.94% | Unkown |
| HY-100857 | PrPSc-IN-1 | / | Unkown | |
| HY-B0361S1 | Aspartame-d5 | / | Unkown | |
| HY-105052 | SC 34301 | / | Unkown | |
| HY-105894 | SC-42867 | Antagonist | / | Unkown |
| HY-10828 | SC-57461 | Inhibitor | / | Unkown |
| HY-111251 | 4SC-207 | / | Unkown | |
| HY-112740 | SC-53228 | Antagonist | / | Unkown |
| HY-113727 | SC-39070 | Antagonist | / | Unkown |
| HY-114786 | SC-44463 | Inhibitor | / | Unkown |
| HY-115360 | IND45193 | Inhibitor | / | Unkown |
| HY-117896 | SC-50605 | Antagonist | / | Unkown |
| HY-118795 | SC-22716 | Inhibitor | / | Unkown |
| HY-119753 | Disobutamide | Inhibitor | / | Unkown |
| HY-120053 | SC-53606 | Antagonist | / | Unkown |
| HY-120776 | SC-51316 | Antagonist | / | Unkown |
| HY-120794 | SC-67655 | / | Unkown | |
| HY-121598 | Actisomide | Inducer | / | Unkown |
| HY-122134 | SC-58272 | Inhibitor | / | Unkown |
| HY-123014 | (Rac)-SC-45694 | Agonist | / | Unkown |
| HY-123014A | SC-45694 lithium | / | Unkown | |
| HY-123229 | Ropizine | / | Unkown | |
| HY-123864 | SC-68448 | Antagonist | / | Unkown |
| HY-124985 | VU6010608 | Modulator | / | Unkown |
| HY-125494 | Droxinavir hydrochloride | Inhibitor | / | Unkown |
| HY-125494A | Droxinavir | Inhibitor | / | Unkown |
| HY-126667 | SC-Val-Cit-PAB | / | Unkown | |
| HY-129782 | SC-55858 | / | Unkown | |
| HY-139678 | SC13 | / | Unkown | |
| HY-14237 | SC-77964 | Inhibitor | / | Unkown |
| HY-156271 | Tubulin polymerization-IN-52 | Inhibitor | / | Unkown |
| HY-162791 | (1s,4s)-C1-Piperidine-C1-cyclohexane-C1 | / | Unkown | |
| HY-168730 | Anticancer agent 259 | Modulator | / | Unkown |
| HY-172133 | HDAC3-IN-6 | / | Unkown | |
| HY-172887 | Kv7.2/Kv7.3 activator-2 | Activator | / | Unkown |
| HY-172944 | GPR40 Activator 3 | Activator | / | Unkown |
| HY-17474AS | Parecoxib-d5 sodium | Inhibitor | / | Unkown |
| HY-17474S | Parecoxib-d3 | Inhibitor | / | Unkown |
| HY-174808 | SC691 | Inhibitor | / | Unkown |
| HY-17509S | Deracoxib-d3 | / | Unkown | |
| HY-175318S | p53 Activator 15 | Activator | / | Unkown |
| HY-176065 | Nav1.2-IN-1 | Inhibitor | / | Unkown |
| HY-178732 | AB-22 | Inhibitor | / | Unkown |
| HY-180145 | Furin-IN-3 | Inhibitor | / | Unkown |
| HY-181980 | SPB07393SC | Inhibitor | / | Unkown |
| HY-182309 | SC83288 | Inhibitor | / | Unkown |
| HY-184428 | PROTAC TSSK1 Degrader-1 | Degrader | / | Unkown |
| HY-184728 | Antifungal agent-169 | Inhibitor | / | Unkown |
| HY-400056 | SC209 intermediate-2 | 99.60% | Unkown | |
| HY-B0561S2 | Spironolactone-d3-1 | / | Unkown | |
| HY-D2996 | BOD-NH-SC | / | Unkown | |
| HY-E70596 | endo-α-1,5-Arabinanases, Paenibacillus polymyxa SC2 | / | Unkown | |
| HY-N12229 | Penipurdin A | Inhibitor | / | Unkown |
| HY-N15703 | Norisocorydine | / | Unkown | |
| HY-N16606 | 2,4-Dihydroxy-6-methoxy-3,5-diprenylacetophenone | Inhibitor | / | Unkown |
| HY-N17737 | Floramanoside F | / | Unkown | |
| HY-N19135 | SB87-H | Inhibitor | / | Unkown |
| HY-N19661 | 1-O-Caffeoyl-3-O-galloyl-β-D-glucopyranose | / | Unkown | |
| HY-N9229 | Myricadenin A | Inhibitor | / | Unkown |
| HY-P3326 | Targeting the bacterial sliding clamp peptide 46 | Inhibitor | / | Unkown |
| HY-RS12473 | SC5D Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS12514 | SCLY Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W1130429 | 4A3-SC10 | Inhibitor | / | Unkown |
| HY-W717425 | SC-60 | / | Unkown | |
| HY-W777079 | Valdecoxib-13C2,15N | / | Unkown | |
| HY-102065R | SC-19220 (Standard) | / | Unkown | |
| HY-106593 | Prorenone | Antagonist | / | Unkown |
| HY-112333 | SC-68376 | Inhibitor | / | Unkown |
| HY-117717 | (Rac)-SC-31391 | Activator | / | Unkown |
| HY-118827S | Vedaprofen-d3 | Inhibitor | / | Unkown |
| HY-120045A | DuP 747 hydrochloride | / | Unkown | |
| HY-120550 | RS 49676 | Inhibitor | / | Unkown |
| HY-120586 | SC-46944 | Inhibitor | / | Unkown |
| HY-122288 | SC 28538 | Inhibitor | / | Unkown |
| HY-123156 | SC-23110 | Inhibitor | / | Unkown |
| HY-123354 | SC 44914 | Inhibitor | / | Unkown |
| HY-123747 | SC-53116 | Agonist | / | Unkown |
| HY-123747A | SC-53116 hydrochloride | Agonist | / | Unkown |
| HY-137089 | Azacosterol dihydrochloride | Inhibitor | / | Unkown |
| HY-137225 | HTS07944 | / | Unkown | |
| HY-157405 | DENV-IN-11 | Inhibitor | / | Unkown |
| HY-163631 | Antibacterial agent 218 | Inhibitor | / | Unkown |
| HY-164525 | SD-7300 | Inhibitor | / | Unkown |
| HY-165401 | SC 19886 | Inhibitor | / | Unkown |
| HY-168776 | (S)-C12-200 | / | Unkown | |
| HY-170520 | Antibiofilm agent-14 | Inhibitor | / | Unkown |
| HY-172411 | GLP-1R agonist 29 | Agonist | / | Unkown |
| HY-172536 | m-PEG30000-NHS ester | / | Unkown | |
| HY-17474S1 | Parecoxib-d5 | Inhibitor | / | Unkown |
| HY-175697 | Glycosyltransferase-IN-2 | Inhibitor | / | Unkown |
| HY-181494 | FAPI-X5 | Inhibitor | / | Unkown |
| HY-184865 | Anticancer agent 340 | / | Unkown | |
| HY-B0361S | Aspartame-d3 | / | Unkown | |
| HY-N12164 | Linearmycin B | Inhibitor | / | Unkown |
| HY-N12871 | Floramanoside D | Inhibitor | / | Unkown |
| HY-N14006 | Louisianin D | / | Unkown | |
| HY-N14139 | Dioxamycin | Inhibitor | / | Unkown |
| HY-N14632 | Louisianin A | / | Unkown | |
| HY-N14633 | Louisianin B | / | Unkown | |
| HY-N14634 | Louisianin C | / | Unkown | |
| HY-RS19952 | Scly Mouse Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS26454 | Scly Rat Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W703540 | Deracoxib-d4 | / | Unkown | |
| HY-P0323 | GP(33-41) | Inhibitor | / | Unkown |
| HY-U00200 | Dicirenone | Antagonist | / | Unkown |
| HY-U00239 | SC58451 | Inhibitor | / | Unkown |
Inhibitory Antibodies
(3)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-P991041 | Turmetabart | 99.75% | Unkown | |
| HY-P99506 | Tamrintamab | 98.51% | Unkown | |
| HY-P990664 | Anti-Melanotransferrin/CD228 Antibody | 99.33% | Unkown |
Compound Screening Libraries
Virtual Screening
Customize Your Library
Drug Screening Service